The results confirm the data on cultured cells and demonstrate a marked inhibition of the acid sphingomyelinase upon treatment with PAPTP + FTY-720 in orthotopic and flank-injected pancreas cancer (Fig. 3A, B). This evidence concerns the gene SMPD1 and pancreatic neoplasm.